nach oben

Erschienen in:

08.04.2022 | Breast

Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy

verfasst von: Xiaoxia Wang, Yuchuan Tan, Daihong Liu, Hesong Shen, Yongchun Deng, Yong Tan, Lei Wang, Yipeng Zhang, Xin Ma, Xiaohua Zeng, Jiuquan Zhang

Erschienen in: European Radiology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate the prevalence of chemotherapy-associated steatohepatitis, quantitate the epicardial adipose tissue (EAT) volume in breast cancer patients, and explore the mediating effect of liver fat content on EAT volume in breast cancer patients who received neoadjuvant chemotherapy (NAC).

Methods

From October 2018 to April 2020, patients were retrospectively reviewed and divided into breast cancer non-NAC and NAC groups. The prevalence of chemotherapy-associated steatohepatitis was evaluated through quantitative MRI mDIXON-Quant examinations by using defined proton density fat fraction cutoffs of liver fat. The EAT volume was quantified on chest CT by semi-automatic volume analysis software. Bootstrap analysis was used in the breast cancer NAC group to test the significance of the mediating effect of liver fat content on EAT volume.

Results

A total of 662 breast cancer patients (non-NAC group: 445 patients; NAC group: 217 patients) were included. The prevalence of chemotherapy-associated steatohepatitis in the NAC group was significantly higher than the prevalence of hepatic steatosis in the non-NAC group (42.8% vs. 33.3%, p < 0.001). EAT volume was measured in 561 of 662 breast cancer patients, and was significantly higher in the NAC group than in the non-NAC group (137.26 ± 53.48 mL vs. 125.14 ± 58.77 mL, p = 0.020). In the breast cancer NAC group, the indirect effect of liver fat content on EAT volume was 2.545 (p < 0.001), and the contribution rate to the effect was 69.1%.

Conclusions

EAT volume was significantly higher in the BC-NAC group than in the BC-non-NAC group.

Key Points

• The prevalence of CASH was as high as 42.8% in BC patients.

• NAC significantly increased the EAT volume in BC patients.

• The liver fat content caused the change of EAT volume through mediating effect.

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30PubMedCrossRef

Derks MGM, van de Velde CJH (2018) Neoadjuvant chemotherapy in breast cancer: more than just downsizing. Lancet Oncol 19:2–3PubMedCrossRef

Gradishar WJ, Anderson BO, Balassanian R et al (2018) Breast cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16:310–320CrossRef

Banke A, Fosbol EL, Ewertz M et al (2019) Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 7:217–224PubMedCrossRef

Matos E, Jug B, Blagus R, Zakotnik B (2016) A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. Arq Bras Cardiol 107:40–47PubMedPubMedCentral

Schumacher JD, Guo GL (2015) Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol 289:40–47PubMedPubMedCentralCrossRef

Dash A, Figler RA, Sanyal AJ, Wamhoff BR (2017) Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol 13:193–204PubMedCrossRef

Meunier L, Larrey D (2020) Chemotherapy-associated steatohepatitis. Ann Hepatol 19:597–601PubMedCrossRef

Vigano L, De Rosa G, Toso C et al (2017) Reversibility of chemotherapy-related liver injury. J Hepatol 67:84–91PubMedCrossRef

10.

Inci F, Karatas F (2019) Paclitaxel-induced hepatic steatosis in patients with breast cancer. J BUON 24:2355–2360PubMed

11.

Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(1264-1281):e1264CrossRef

12.

Hui SCN, So HK, Chan DFY et al (2018) Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease. Eur J Radiol 107:7–13PubMedCrossRef

13.

Yokoo T, Shiehmorteza M, Hamilton G et al (2011) Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 258:749–759PubMedPubMedCentralCrossRef

14.

Meisamy S, Hines CD, Hamilton G et al (2011) Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 258:767–775PubMedPubMedCentralCrossRef

15.

Chaosuwannakit N, D’Agostino R Jr, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166–172PubMedCrossRef

16.

Koelwyn GJ, Lewis NC, Ellard SL et al (2016) Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy. Oncologist 21:141–149PubMedPubMedCentralCrossRef

17.

Zhang W, Xie K, Fu S et al (2019) Comparison of the incidence of perioperative cardiovascular risk events among patients with and without a history of neoadjuvant chemotherapy. Minerva Anestesiol 85:822–829PubMed

18.

Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552–2565PubMedPubMedCentralCrossRef

19.

Zeng X, Wang X, Chen H et al (2020) Evaluating the image quality of monoenergetic images from dual-energy computed tomography with low-concentration and low-flow-rate contrast media for the arterials supply to the nipple-areola complex in breast cancer compared with conventional computed tomography angiography. J Comput Assist Tomogr 44:921–927PubMedPubMedCentralCrossRef

20.

Eisenberg E, McElhinney PA, Commandeur F et al (2020) Deep learning-based quantification of epicardial adipose tissue volume and attenuation predicts major adverse cardiovascular events in asymptomatic subjects. Circ Cardiovasc Imaging 13:e009829PubMedPubMedCentralCrossRef

21.

Russo R, Di Iorio B, Di Lullo L, Russo D (2018) Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations. J Nephrol 31:847–853PubMedCrossRef

22.

Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE (2020) Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 51:728–736PubMedPubMedCentralCrossRef

23.

Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H (2020) Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res 126:679–704PubMedCrossRef

24.

Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:1724–1745PubMedPubMedCentralCrossRef

25.

Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20PubMedCrossRef

26.

Tana C, Ballestri S, Ricci F et al (2019) Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health 16

27.

Kuhn JP, Meffert P, Heske C et al (2017) Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. Radiology 284:706–716PubMedCrossRef

28.

Kuhn JP, Hernando D, Munoz del Rio A et al (2012) Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 265:133–142PubMedPubMedCentralCrossRef

29.

Kwon EY, Kim YR, Kang DM, Yoon KH, Lee YH (2021) Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. Clin Imaging 76:53–59PubMedCrossRef

30.

Gaubeta S, Klinghammer L, Jahn D, Schuhback A, Achenbach S, Marwan M (2014) Epicardial fat and coronary artery calcification in patients on long-term hemodialysis. J Comput Assist Tomogr 38:768–772PubMedCrossRef

31.

Hell MM, Achenbach S, Schuhbaeck A, Klinghammer L, May MS, Marwan M (2016) CT-based analysis of pericoronary adipose tissue density: relation to cardiovascular risk factors and epicardial adipose tissue volume. J Cardiovasc Comput Tomogr 10:52–60PubMedCrossRef

32.

Marwan M, Koenig S, Schreiber K et al (2019) Quantification of epicardial adipose tissue by cardiac CT: influence of acquisition parameters and contrast enhancement. Eur J Radiol 121:108732PubMedCrossRef

33.

Elsanhoury A, Nelki V, Kelle S, Van Linthout S, Tschope C (2021) Epicardial fat expansion in diabetic and obese patients with heart failure and preserved ejection fraction-a specific HFpEF phenotype. Front Cardiovasc Med 8:720690PubMedPubMedCentralCrossRef

34.

Artz NS, Haufe WM, Hooker CA et al (2015) Reproducibility of MR-based liver fat quantification across field strength: same-day comparison between 1.5T and 3T in obese subjects. J Magn Reson Imaging 42:811–817PubMedPubMedCentralCrossRef

35.

Serai SD, Dillman JR, Trout AT (2017) Proton density fat fraction measurements at 1.5- and 3-T hepatic MR imaging: same-day agreement among readers and across two imager manufacturers. Radiology 284:244–254PubMedCrossRef

36.

Tang A, Tan J, Sun M et al (2013) Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267:422–431PubMedPubMedCentralCrossRef

37.

Jayakumar S, Middleton MS, Lawitz EJ et al (2019) Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol 70:133–141PubMedCrossRef

38.

Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353PubMedCrossRef

39.

Lancellotti P, Anker SD, Donal E et al (2015) EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 16:466–470PubMedCrossRef

40.

Madonna R, Massaro M, Scoditti E, Pescetelli I, De Caterina R (2019) The epicardial adipose tissue and the coronary arteries: dangerous liaisons. Cardiovasc Res 115:1013–1025PubMedCrossRef

41.

Packer M (2018) Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 71:2360–2372PubMedCrossRef

42.

Christensen RH, von Scholten BJ, Hansen CS et al (2019) Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol 18:114PubMedPubMedCentralCrossRef

43.

Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153PubMedCrossRef

44.

van den Berg EH, Wolters AAB, Dullaart RPF et al (2019) Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 39:1343–1354PubMedPubMedCentralCrossRef

45.

Xia LY, Hu QL, Zhang J, Xu WY, Li XS (2020) Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol 18:129PubMedPubMedCentralCrossRef

46.

Idilman IS, Aniktar H, Idilman R et al (2013) Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 267:767–775PubMedCrossRef

Titel: Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy
verfasst von: Xiaoxia Wang
Yuchuan Tan
Daihong Liu
Hesong Shen
Yongchun Deng
Yong Tan
Lei Wang
Yipeng Zhang
Xin Ma
Xiaohua Zeng
Jiuquan Zhang
Publikationsdatum: 08.04.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 7/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-022-08581-1

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy